The Effect of Bitter Taste Receptor Agonists on The Gastrointestinal Tract, Hunger and Food Intake

The Role of Bitter Taste Receptors Expressed in the Gastrointestinal Tract in Altering Food Intake and Gastrointestinal Motility

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02759926

Enrollment

Registered

2016-05-03

Start date

2011-08-31

Completion date

Unknown

Last updated

2016-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Obesity

Keywords

Healthy volunteers, Obesity, Bitter

Brief summary

In this study, the investigators aimed at evaluating the role of bitter taste receptors in the gastrointestinal tract (GIT). Intragastric or intraduodenal administration of denatonium benzoate (DB) or quinine hydrochloride were compared with placebo administration for their effects on lingual sensitivity, gastrointestinal motility (both in the fasted and fed state), gut hormone release (motilin, ghrelin, glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK)) and food intake. Differences between lean and obese subjects will be evaluated.

Interventions

DRUGDenatonium benzoate

DRUGQuinine hydrochloride

DRUGTap water

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* BMI\>30 kg/m² for the obese volunteers * BMI\<30 kg/m² for the lean volunteers * Subject is capable and willing to give informed consent * Female volunteers of child bearing potential must use oral, injected or implanted hormonal methods of contraception

Exclusion criteria

* Female volunteer is pregnant or breastfeeding * Gastrointestinal diseases, major abdominal surgery * Major psychiatric illnesses * Volunteers that use drugs affecting the GIT or the central nervous system (CNS) * Volunteers that suffer from diabetes mellitus * Volunteers suffering from an endocrine disease such as diabetes, Cushing's disease, Addison's disease, hypothalamic tumor… * Volunteers that have undergone surgical procedure for weight loss

Design outcomes

Primary

Measure	Time frame
Change in gastrointestinal motility measured by antroduodenal high-resolution manometry	2 hours after administration, continuous measurement with high resolution manometry

Secondary

Measure	Time frame
Change in gut hormone release measured by specific radioactive immunoassays	2 hours after administration, blood sample every 10 min
Change in food intake measured by the caloric content of the meal	ad libitum food intake for 1 hour, 40 min after administration
Change in subjective hunger and satiety scores measured by visual analogue scales of 100 mm	2 hours after administration, assessment every 5 min

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026